Literature DB >> 19642202

Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice.

George M Alley1, Jason A Bailey, Demao Chen, Balmiki Ray, Lakshman K Puli, Heikki Tanila, Pradeep K Banerjee, Debomoy K Lahiri.   

Abstract

Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-beta peptides (Abeta) occurs as a result of aberrant processing of the full-length Abeta precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Abeta and improves cognition in transgenic mice with high brain levels of Abeta. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Abeta production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 muM), decreased levels of secreted APP and Abeta(1-40). Levels of the potentially amylodogenic Abeta(1-42) were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Abeta(1-42) secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Abeta(1-42), oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 microM and significantly reduced the cortical levels of soluble Abeta(1-42). The ratio of Abeta(1-40)/Abeta(1-42) increased in treated mice, suggesting effects on the gamma-secretase complex. Thus, memantine reduces the levels of Abeta peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Abeta in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Abeta level has therapeutic implications for neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19642202      PMCID: PMC2783840          DOI: 10.1002/jnr.22172

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  64 in total

Review 1.  The chemical biology of clinically tolerated NMDA receptor antagonists.

Authors:  Huei-Sheng Vincent Chen; Stuart A Lipton
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

2.  APP processing and synaptic function.

Authors:  Flavio Kamenetz; Taisuke Tomita; Helen Hsieh; Guy Seabrook; David Borchelt; Takeshi Iwatsubo; Sangram Sisodia; Roberto Malinow
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

3.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 4.  The C-terminus of the beta protein is critical in amyloidogenesis.

Authors:  J T Jarrett; E P Berger; P T Lansbury
Journal:  Ann N Y Acad Sci       Date:  1993-09-24       Impact factor: 5.691

5.  Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

Authors:  J Kornhuber; J Bormann; M Hübers; K Rusche; P Riederer
Journal:  Eur J Pharmacol       Date:  1991-04-25       Impact factor: 4.432

6.  Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission.

Authors:  U E Honegger; G Quack; U N Wiesmann
Journal:  Pharmacol Toxicol       Date:  1993-10

7.  Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells.

Authors:  K Y Hostetler; D D Richman
Journal:  Biochem Pharmacol       Date:  1982-12-01       Impact factor: 5.858

8.  Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

Authors:  C G Parsons; R Gruner; J Rozental; J Millar; D Lodge
Journal:  Neuropharmacology       Date:  1993-12       Impact factor: 5.250

9.  Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination.

Authors:  G J Brewer; J R Torricelli; E K Evege; P J Price
Journal:  J Neurosci Res       Date:  1993-08-01       Impact factor: 4.164

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  46 in total

1.  Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals.

Authors:  Soong Ho Kim; Paul E Fraser; David Westaway; Peter H St George-Hyslop; Michelle E Ehrlich; Sam Gandy
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

Review 2.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Authors:  Miren Ettcheto; Elena Sánchez-López; Yaiza Gómez-Mínguez; Henrry Cabrera; Oriol Busquets; Carlos Beas-Zarate; Maria Luisa García; Eva Carro; Gemma Casadesus; Carme Auladell; Manuel Vázquez Carrera; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

4.  Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.

Authors:  Scott E Counts; Balmiki Ray; Elliott J Mufson; Sylvia E Perez; Bin He; Debomoy K Lahiri
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

5.  Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.

Authors:  Erin R Hascup; Sarah O Broderick; Mary K Russell; Yimin Fang; Andrzej Bartke; Heather A Boger; Kevin N Hascup
Journal:  J Neurochem       Date:  2019-01-03       Impact factor: 5.372

Review 6.  The "aged garlic extract:" (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD).

Authors:  B Ray; N B Chauhan; D K Lahiri
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI.

Authors:  S Sekar; E Jonckers; M Verhoye; R Willems; J Veraart; J Van Audekerke; J Couto; M Giugliano; K Wuyts; S Dedeurwaerdere; J Sijbers; C Mackie; L Ver Donck; T Steckler; A Van der Linden
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

8.  Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.

Authors:  Stefanie Dedeurwaerdere; Cindy Wintmolders; Roel Straetemans; Darrel Pemberton; Xavier Langlois
Journal:  Psychopharmacology (Berl)       Date:  2010-10-31       Impact factor: 4.530

9.  Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism.

Authors:  Craig A Erickson; Balmiki Ray; Logan K Wink; Baindu L Bayon; Ernest V Pedapati; Rebecca Shaffer; Tori L Schaefer; Debomoy K Lahiri
Journal:  J Psychiatr Res       Date:  2016-09-09       Impact factor: 4.791

10.  Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells.

Authors:  Balmiki Ray; Pradeep K Banerjee; Nigel H Greig; Debomoy K Lahiri
Journal:  Neurosci Lett       Date:  2009-12-04       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.